How effective are the drugs pregabalin and celecoxib in relieving pain after laparoscopic gall bladder surgery?

Authors
Category Primary study
Registry of TrialsANZCTR
Year 2012
INTERVENTION: premedication 1 hour before the surgery with Group pregabalin: pregabalin 150 mg + matched celecoxib placebo orally Group celecoxib: celecoxib 400 mg + pregabalin placebo orally Group pregabalin/celecoxib: pregabalin 150 mg + celecoxib 400 mg orally Group placebo: pregabalin placebo + celecoxib placebo orally Matched celecoxib and pregabalin placebos are identical in shape, size and colour to celecoxib and pregabalin tablets, but they differ from the original tablets in that they contain no active ingredients. 12 hours after the premedication, second dose of study drugs (pregabalin 150 mg/ celecoxib 200 mg/ combination/ placebo) given. CONDITION: pain after laparoscopic cholecystectomy PRIMARY OUTCOME: postoperative pain and PCA fentanyl requirements are assessed. Assessment of pain at rest & with movement with verbal rating scale 0‐10 with 0 representing no pain and 10 the worst imaginable pain SECONDARY OUTCOME: Nausea & vomiting assessed with the 4 point ordinal scale ; ; 0‐ no N +V ; 1‐ mild N+V ; 2‐ moderate N+V ; 3‐ severe N+V Other side effects‐headache/light headedness/dizziness/visual disturbance‐ diplopia/pruritus/difficulty in walking or concentrating/drowsiness & difficulty in staying awake/itchiness/drymouth/confusion. The above side effects are noted with yes/no ordinal scale. assessment of preoperative anxiety with the verbal rating scale 0‐10. satisfaction with pain relief by scale of 0‐10, 0, completely dissatisfied; 10‐ completely satisfied sedation scores as assessed by 4 point ordinal scale ; 0‐ none ,completely awake ; 1‐ mild, occasional drowsy, easy to rouse ; 2‐ moderate, arousable, but not able to stay awake ; 3‐ severe, difficult to rouse or unarousable INCLUSION CRITERIA: ASA I/II patients, 18‐70 years, undergoing laparoscopic cholecystectomy with minimal or no health issues.
Epistemonikos ID: 647e083ea5cc72cfb150d93c10b1de0ee278eff3
First added on: Aug 25, 2024